XML 59 R48.htm IDEA: XBRL DOCUMENT
v3.25.2

Divestiture of Preclinical Small Molecule Programs (Details) - USD ($) $ / shares in Units, $ in Thousands, shares in Millions |  | 1 Months Ended | 3 Months Ended | 6 Months Ended
--- | --- | --- | --- | ---
Mar. 01, 2024 | Dec. 31, 2024 | Jun. 30, 2025 | Jun. 30, 2024 | Jun. 30, 2025 | Jun. 30, 2024
Disposal Groups, Including Disposal Of Long-Lived Assets [Line Items] |  |  |  |  |  |
Equity consideration received in the divestiture of small molecule programs (Note 10) |  |  |  |  | $ 0 | $ 15,000
Convertible preferred stock, par value (usd per share) |  | $ 0.01 | $ 0.01 |  | $ 0.01 |
Gain from divestiture of small molecule programs |  |  | $ 0 | $ 0 | $ 0 | 14,537
Tenvie Therapeutics, Inc |  |  |  |  |  |
Disposal Groups, Including Disposal Of Long-Lived Assets [Line Items] |  |  |  |  |  |
Equity consideration received in the divestiture of small molecule programs (Note 10) | $ 15,000 |  |  |  |  |
Noncash or part noncash divestiture, milestone payments, to be received |  |  | $ 1,200,000 |  | $ 1,200,000 |
Future royalties, threshold after first commercial sale |  |  | 10 years |  | 10 years |
Tenvie Therapeutics, Inc | Series A Preferred Stock |  |  |  |  |  |
Disposal Groups, Including Disposal Of Long-Lived Assets [Line Items] |  |  |  |  |  |
Number of shares converted in simple agreement for future equity (in shares) |  | 15.0 |  |  |  |
Convertible preferred stock, par value (usd per share) |  | $ 0.0001 |  |  |  |
Fair value of shares converted in simple agreement for future equity |  | $ 15,000 |  |  |  |
Fair value of investment |  | $ 15,000 | $ 15,000 |  | $ 15,000 |
Venture Backed Private Company ("VBPC") |  |  |  |  |  |
Disposal Groups, Including Disposal Of Long-Lived Assets [Line Items] |  |  |  |  |  |
Equity consideration received in the divestiture of small molecule programs (Note 10) | $ 15,000 |  |  |  |  |
Gain from divestiture of small molecule programs |  |  |  |  |  | $ 14,500

X
- Definition Disposal Group, Including Discontinued Operation, Consideration, Equity Interest Received, Number Of Shares + References No definition available. + Details
Name: | dnli_DisposalGroupIncludingDiscontinuedOperationConsiderationEquityInterestReceivedNumberOfShares
Namespace Prefix: | dnli_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Disposal Group, Including Discontinued Operation, Consideration, Equity Interest Received, Value Assigned + References No definition available. + Details
Name: | dnli_DisposalGroupIncludingDiscontinuedOperationConsiderationEquityInterestReceivedValueAssigned
Namespace Prefix: | dnli_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Disposal Groups, Including Disposal Of Long-Lived Assets + References No definition available. + Details
Name: | dnli_DisposalGroupsIncludingDisposalOfLongLivedAssetsLineItems
Namespace Prefix: | dnli_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Future Royalties, Threshold After First Commercial Sale + References No definition available. + Details
Name: | dnli_NoncashOrPartNoncashDivestitureFutureRoyaltiesThresholdAfterFirstCommercialSale
Namespace Prefix: | dnli_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | instant

X
- Definition Noncash Or Part Noncash Divestiture, Milestone Payments, To Be Received + References No definition available. + Details
Name: | dnli_NoncashOrPartNoncashDivestitureMilestonePaymentsToBeReceived
Namespace Prefix: | dnli_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-5 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476148/220-40-50-21 + Details
Name: | us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as noncurrent. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A + Details
Name: | us-gaap_EquitySecuritiesFVNINoncurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of noncash consideration received for selling an asset or business through a noncash (or part noncash) transaction. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5 + Details
Name: | us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details
Name: | us-gaap_PreferredStockParOrStatedValuePerShare
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Details
Name: | us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=dnli_TenvieTherapeuticsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=dnli_VentureBackedPrivateCompanyVBPCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |